PharmaSource podcast featuring EXOZ CCO, Perriman
investorpodcastperrimanNCT
PharmaSource podcast: How EXOZ Is Running a 10-CDMO RFP for CDMO SelectionSeptember 9, 2026
Dr. Paul Opgenorth from eXoZymes at Curia in Italy
investorperrimanNCT
eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCTSeptember 8, 2026
WBMI: Scaling without Cells
investornutraceuticalspress clippingsperrimanNCT
World Bio Market Insights: Scaling without CellsSeptember 3, 2026
Inside eXoZymes’ Strategic Shift: Building a Compounding Value Flywheel
investorpress clippingsNCT
Slack Capital: Inside EXOZ’ strategic shift - building a compounding value flywheelAugust 27, 2026
WTR: EXOZ 2Q26 update - from platform validation to commercial execution
investorpress clippingsNCT
WTR: EXOZ 2Q26 update - from platform validation to commercial executionAugust 25, 2026
Q&A: Tyler Korman, Michael Heltzen, Damien Perriman
heltzeninvestorvideoperrimankorman
Transcript: Q2 2026 investor update from EXOZAugust 21, 2026
Q2 2026 investor update
heltzenpress releaseinvestor
eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET todayAugust 20, 2026
NCT process advances beyond original commercial-scale economic targets
press releaseinvestorscienceperrimanNCT
eXoZymes' NCT process achieves 10-fold productivity increase, advancing beyond original commercial-scale economic targetsAugust 18, 2026
EXOZ to host Q2 2026 investor update on Aug 20 @ 5PM Eastern
press releaseinvestor
EXOZ to host Q2 2026 investor update on Aug 20 @ 5PM EasternAugust 11, 2026
EXOZ and LBNL awarded Genesis Mission grant from DOE
heltzenpress releasescience
eXoZymes selected for DoE’s Genesis Mission to advance AI-powered digital twins for cell-free biomanufacturingJuly 23, 2026
Previous page
Page 1 of 15
Next page